NCT07547098 Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome
| NCT ID | NCT07547098 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Cardiovascular Diseases (CVD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2031-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,000 participants in total. It began in 2026-03-01 with a primary completion date of 2031-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage. * Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping. * Willingness to participate and provision of written informed consent. * Ability to complete baseline assessment and follow-up. * Full civil capacity and ability to understand study information. Exclusion Criteria: * Refusal to provide written informed consent. * Severe psychiatric disease or cognitive impairment precluding participation. * End-stage disease with expected survival less than 1 year. * Long-term absence more than 6 months preventing reliable follow-up. * Participation in another clinical study that may interfere with endpoint adjudication. * Missing key fields preventing linkage of examinations, imaging, and outcomes.
Contact & Investigator
Dajun Chai
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT07547098 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cardiovascular Diseases (CVD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07547098 currently recruiting?
Yes, NCT07547098 is actively recruiting participants. Contact the research team at dajunchai-fy@fjmu.edu.cn for enrollment information.
Where is the NCT07547098 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07547098 clinical trial?
NCT07547098 is sponsored by First Affiliated Hospital of Fujian Medical University. The principal investigator is Dajun Chai at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 8,000 participants.